Can a new antibody boost recovery after severe stroke?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>18 years old * Acute ischemic stroke due to an isolated proximal anterior large vessel occlusion (M1 and M2 segment of the middle cerebral artery, terminal internal carotid artery (TICA)) * Indication of EVT within the time window of 0 to 24 hours in participants treated with or without intravenous thrombolysis. * Presenting with a baseline infarct core volume assessed on the MRI (DWI sequence) or CT scan with an ASPECTS\<6 * Woman \<49 years old must have a negative serum/urine pregnancy test at baseline Exclusion Criteria: * Possible tandem occlusion on the baseline imaging, potentially requiring stenting * Significant pre-stroke disability (mRS\>2) * Patients under or needing immediate dual anti-platelet therapy (DAPT) within the first 24 hours after the cessation of glenzocimab or placebo infusion * Significant mass effect with midline shift as confirmed on CT/MRI * Gastrointestinal or urinary tract haemorrhage in previous 21 days * Patient with intracranial haemorrhage * Platelet count \<100 000 mm3 * Known hypersensitivity to glenzocimab or to any of the excipients * Known hypersensitivity to the gadolinium used for the brain MRI perfusion, or one of its excipients * Known Severe renal insufficiency (Grades 4-5) with a glomerular filtration rate \< 30mL/Min/1.73m2 * Patients receiving anticoagulants within the last 24 hours and: * For heparin, an elevated aPTT -greater than upper limit of normal for laboratory * For vitamin K antagonists (ex: warfarin), an INR \>1.7; * For direct thrombin inhibitors or direct factor Xa inhibitors, a plasmatic dosage of the drug greater than upper limit of normal for laboratory * Pregnant or breastfeeding woman * Participation in another interventional clinical investigational drug or medical device trial within 30 days prior to the inclusion.